<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4486">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048526</url>
  </required_header>
  <id_info>
    <org_study_id>NT-004</org_study_id>
    <nct_id>NCT03048526</nct_id>
  </id_info>
  <brief_title>Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease</brief_title>
  <official_title>Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novaliq GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novaliq GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mild to moderate dry eye disease will be randomized to receive either
      NovaTears® or Hydrabak® eye drops as control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear film thickness as measured with high resolution optical coherence tomography</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid layer thickness</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive tear break up time</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic Meibomian Gland Imaging</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blink frequency</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom VAS</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal fluorescein staining</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival lissamine green staining</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer I test</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear film break up time</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface disease index</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>NovaTears®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrabak®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unpreserved sodium chloride (0.9%) eye drops in ABAK® system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovaTears®</intervention_name>
    <description>Topical eye drops for lubrication of the ocular surface</description>
    <arm_group_label>NovaTears®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrabak®</intervention_name>
    <description>Eye drops</description>
    <arm_group_label>Hydrabak®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged over 18 years

          -  History of dry eye disease for at least 3 months before the screening visit

          -  Be able and willing to follow instructions, including participation in all study
             assessments and visits

          -  Signed and dated written informed consent

        Exclusion Criteria:

          -  Have any clinically significant slit-lamp findings at the screening visit that may
             include trauma, Steven Johnson syndrome, and/or in the opinion of the investigator
             may interfere with study parameters

          -  Participation in a clinical trial in the 4 weeks preceding the before the screening
             visit

          -  Active ocular allergies or ocular allergies that are expected to be active during the
             study period

          -  Pregnancy, planned pregnancy or lactating

          -  Known hypersensitivity to any component of the study medication

          -  Any medical or surgical history, disorder or disease such as acute or chronic severe
             organic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garhoefer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novaliq GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serge Kosobokovs, MD</last_name>
    <phone>+49 (0) 62215 02 59-0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhoefer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>February 7, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
